Recent studies have shed light on the correlation between co-mutations and unfavorable outcomes, as well as the underlying mechanism that promotes resistance in EGFR-mutant lung adenocarcinoma (Vokes et al. 2022; Liu et al. 2022). The gene discussed is EGFR; the disease is lung adenocarcinoma.